- THIO and ionizing radiation combination shown to significantly
decrease cell proliferation and produce potent anticancer effects
in highly aggressive, treatment-resistant childhood brain
cancer
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the
“Company”), a clinical-stage biopharmaceutical company developing
targeted immunotherapies for cancer, today announced that Dr.
Rachid Drissi, Principal Investigator at the Center for Childhood
Cancer Research, Nationwide Children’s Hospital, and Associate
Professor at Ohio State University, will present an abstract
detailing the potency of THIO, MAIA’s telomere-targeting agent, as
treatment for pediatric brain cancers at the American Association
for Cancer Research (AACR) Annual Meeting taking place April 5–10,
2024 in San Diego, California.
The research was conducted in collaboration with Nationwide
Children's Hospital and led by Dr. Drissi. The study explored the
combination of THIO and ionizing radiation (IR) treatments to
induce direct anticancer effects and stimulate anti-tumor immunity
in diffuse intrinsic pontine glioma (DIPG).
DIPG, a very difficult-to-treat and high-risk childhood cancer,
is a central nervous system (CNS) tumor that forms in the
brainstem. Scientists from Nationwide Children’s Hospital and MAIA
have shown that THIO synergistically sensitizes DIPG cells to
ionizing radiation (IR), significantly decreasing cell
proliferation.
“At the AACR Annual Meeting, we will present study results
demonstrating the potential for THIO and IR combinational
treatments to stimulate anti-tumor immunity through activation of
the STING pathway, one of the key regulators of immune responses in
a DIPG model,” said Sergei M. Gryaznov, PhD., MAIA’s Chief
Scientific Officer. “Unfortunately, prognosis for DIPG is dismal
with a survival rate of less than one year, and radiotherapy, the
only standard of care for DIPG, extends survival by only a few
months. Immunotherapy is emerging as a potential alternative. Novel
therapies that activate the immune system while evading tumor
immunosuppression are in high demand in the field of cancer
research.”
“MAIA is excited to see that the results of our scientific
collaborative work with the Nationwide Children’s Hospital were
accepted for presentation at the AACR Annual Meeting, a gathering
of many of the best minds in cancer research from institutions all
over the world,” added Vlad Vitoc, M.D., CEO of MAIA.
MAIA’s presentation at the 2024 AACR Annual Meeting
Abstract #: 5108
Abstract title: Immunomodulatory and Antitumor Effect of
Radiation and Induced Telomere Damage to Treat Pediatric High-grade
Gliomas
Authors:
- Banlanjo Umaru, Shiva Senthil Kumar (Center for Childhood
Cancer Research, Nationwide Children's Hospital, Columbus, OH)
- Sergei M. Gryaznov (MAIA Biotechnology, Inc., Chicago, IL)
- Rachid Drissi (Center for Childhood Cancer Research, Nationwide
Children's Hospital, Columbus, OH; The Ohio State University
College of Medicine, Columbus, OH)
Presenter: Rachid Drissi
Session date and time: Tuesday April 09, 2024, 09:00AM – 12:30PM
(Section 43)
About THIO
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class
investigational telomere-targeting agent currently in clinical
development to evaluate its activity in Non-Small Cell Lung Cancer
(NSCLC). Telomeres, along with the enzyme telomerase, play a
fundamental role in the survival of cancer cells and their
resistance to current therapies. The modified nucleoside
6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent
telomeric DNA modification, DNA damage responses, and selective
cancer cell death. THIO-damaged telomeric fragments accumulate in
cytosolic micronuclei activating both innate (cGAS/STING) and
adaptive (T-cell) immune responses. The sequential treatment with
THIO followed by PD-(L)1 inhibitors resulted in profound and
persistent tumor regression in advanced, in vivo cancer models by
induction of cancer type–specific immune memory. THIO is presently
developed as a second or later line of treatment for NSCLC for
patients that have progressed beyond the standard-of-care regimen
of existing checkpoint inhibitors.
About Nationwide Children’s Hospital
Named to the Top 10 Honor Roll on U.S. News & World Report’s
2023-24 list of “Best Children’s Hospitals,” Nationwide Children’s
Hospital is one of America’s largest not-for-profit free-standing
pediatric health care systems providing unique expertise in
pediatric population health, behavioral health, genomics and health
equity as the next frontiers in pediatric medicine, leading to best
outcomes for the health of the whole child. Integrated clinical and
research programs, as well as prioritizing quality and safety, are
part of what allows Nationwide Children’s to advance its unique
model of care. NationwideChildrens.org
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on
the development and commercialization of potential first-in-class
drugs with novel mechanisms of action that are intended to
meaningfully improve and extend the lives of people with cancer.
Our lead program is THIO, a potential first-in-class cancer
telomere targeting agent in clinical development for the treatment
of NSCLC patients with telomerase-positive cancer cells. For more
information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of
historical facts contained in this press release, are
forward-looking statements. Forward-looking statements are subject
to known and unknown risks, uncertainties, and other factors that
may cause our or our industry’s actual results, levels or activity,
performance or achievements to be materially different from those
anticipated by such statements. The use of words such as “may,”
“might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “project,” “intend,” “future,” “potential,”
or “continue,” and other similar expressions are intended to
identify forward looking statements. However, the absence of these
words does not mean that statements are not forward-looking. For
example, all statements we make regarding (i) the initiation,
timing, cost, progress and results of our preclinical and clinical
studies and our research and development programs, (ii) our ability
to advance product candidates into, and successfully complete,
clinical studies, (iii) the timing or likelihood of regulatory
filings and approvals, (iv) our ability to develop, manufacture and
commercialize our product candidates and to improve the
manufacturing process, (v) the rate and degree of market acceptance
of our product candidates, (vi) the size and growth potential of
the markets for our product candidates and our ability to serve
those markets, and (vii) our expectations regarding our ability to
obtain and maintain intellectual property protection for our
product candidates, are forward looking. All forward-looking
statements are based on current estimates, assumptions and
expectations by our management that, although we believe to be
reasonable, are inherently uncertain. Any forward-looking statement
expressing an expectation or belief as to future events is
expressed in good faith and believed to be reasonable at the time
such forward-looking statement is made. However, these statements
are not guarantees of future events and are subject to risks and
uncertainties and other factors beyond our control that may cause
actual results to differ materially from those expressed in any
forward-looking statement. Any forward-looking statement speaks
only as of the date on which it was made. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise, except as required by law. In this release, unless the
context requires otherwise, “MAIA,” “Company,” “we,” “our,” and
“us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240306724695/en/
Investor Relations Contact +1 (872) 270-3518
ir@maiabiotech.com
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024